Our September issue is live

In this large edition we include over 30 profiles of active partnering companies and a selection of editorials all focused on either antibody technologies, immuno-oncology or cell and gene therapies.

Advertisement

  • Northern Antibiotics is developing improved versions of polymyxins to help fight against resistant Gram-negative bacteria and has three parallel programs in development.

    • Northern Antibiotics Ltd.
    Advertisement Feature
  • The Swiss pharmaceutical company BioVersys is developing next-generation antimicrobial drugs with unique modes of action targeting a range of multidrug-resistant bacteria.

    • BioVersys AG
    Advertisement Feature
  • Lysando AG’s Artilysin platform technology is producing novel antimicrobial proteins with a unique mode of action and a wide range of applications, from human and veterinary medicine to the food and cosmetics industry. Lysando is licensing the technology to companies all around the world.

    • Lysando AG
    Advertisement Feature
  • Cytophage has developed a versatile bacteriophage-based antibacterial and antiviral technology targeting human and agricultural infectious diseases. With lead programs in avian and swine bacterial infections and in COVID-19, the company is seeking to expand its partnership network.

    • Cytophage Technologies
    Advertisement Feature
  • Amicrobe engineers biologics-as-materials that are applied locally in surgery and trauma to prevent and treat life-threatening infections.

    • Amicrobe, Inc.
    Advertisement Feature
  • Biofilms are a major contributor to the global challenge of antibiotic resistance. BioFilm Control is leading the way in eradicating the biofilm barrier and overcoming antibiotic resistance with compounds that have blockbuster potential.

    • BioFilm Control
    Advertisement Feature
  • Protein engineering company Lytica Therapeutics is pioneering the use of α-helical stapled antimicrobial peptides (StAMPs) to lyse and kill multidrug-resistant bacteria.

    • Lytica Therapeutics, Inc.
    Advertisement Feature
Tackling antimicrobial resistance

Tackling antimicrobial resistance

Antimicrobial resistance remains a global health threat, in this collection we present companies developing therapeutics to urgently fight against a range of potentially dangerous pathogens.
Collection